CN100591691C - 新型抗肿瘤化合物 - Google Patents

新型抗肿瘤化合物 Download PDF

Info

Publication number
CN100591691C
CN100591691C CN200380101647A CN200380101647A CN100591691C CN 100591691 C CN100591691 C CN 100591691C CN 200380101647 A CN200380101647 A CN 200380101647A CN 200380101647 A CN200380101647 A CN 200380101647A CN 100591691 C CN100591691 C CN 100591691C
Authority
CN
China
Prior art keywords
cancer
compound
valine
allo
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200380101647A
Other languages
English (en)
Chinese (zh)
Other versions
CN1705677A (zh
Inventor
G·T·费尔克洛思
M·埃利塞斯
H·萨萨克
P·M·阿维莱斯·马里亚诺
M·D·C·奎斯瓦斯·马尔尚特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN1705677A publication Critical patent/CN1705677A/zh
Application granted granted Critical
Publication of CN100591691C publication Critical patent/CN100591691C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN200380101647A 2002-10-18 2003-10-20 新型抗肿瘤化合物 Expired - Fee Related CN100591691C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBPCT/GB02/004735 2002-10-18
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GB0304367.6 2003-02-26
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
GB0314725.3 2003-06-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101122538A Division CN101077885A (zh) 2002-10-18 2003-10-20 新型抗肿瘤化合物

Publications (2)

Publication Number Publication Date
CN1705677A CN1705677A (zh) 2005-12-07
CN100591691C true CN100591691C (zh) 2010-02-24

Family

ID=32110555

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200380101647A Expired - Fee Related CN100591691C (zh) 2002-10-18 2003-10-20 新型抗肿瘤化合物
CNA2007101122538A Pending CN101077885A (zh) 2002-10-18 2003-10-20 新型抗肿瘤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101122538A Pending CN101077885A (zh) 2002-10-18 2003-10-20 新型抗肿瘤化合物

Country Status (10)

Country Link
EP (1) EP1572726B1 (https=)
JP (1) JP4430009B2 (https=)
CN (2) CN100591691C (https=)
BR (1) BR0315489A (https=)
CA (1) CA2501089C (https=)
ES (1) ES2357644T3 (https=)
MX (1) MXPA05004133A (https=)
NZ (1) NZ539093A (https=)
WO (1) WO2004035613A2 (https=)
ZA (1) ZA200502926B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
DE102008005097B4 (de) * 2008-01-18 2011-04-07 Leibnitz-Institut für Meereswissenschaften Antitumoraler Cyclodepsipeptide, deren Herstellung und Verwendung
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
ME02395B (me) 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
JP2023503318A (ja) 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85107296A (zh) * 1984-09-25 1987-04-08 田道制药株式会社 制备胃肠外营养溶液的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85107296A (zh) * 1984-09-25 1987-04-08 田道制药株式会社 制备胃肠外营养溶液的方法

Also Published As

Publication number Publication date
CA2501089C (en) 2012-07-17
BR0315489A (pt) 2005-08-23
CA2501089A1 (en) 2004-04-29
ZA200502926B (en) 2006-02-22
WO2004035613A3 (en) 2004-07-29
EP1572726A2 (en) 2005-09-14
MXPA05004133A (es) 2005-10-05
CN1705677A (zh) 2005-12-07
NZ539093A (en) 2007-10-26
CN101077885A (zh) 2007-11-28
ES2357644T3 (es) 2011-04-28
JP2006517195A (ja) 2006-07-20
EP1572726B1 (en) 2010-12-08
JP4430009B2 (ja) 2010-03-10
WO2004035613A2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
US7683028B2 (en) Kahalalide compositions
JP5372096B2 (ja) 新規な抗腫瘍化合物
CN100591691C (zh) 新型抗肿瘤化合物
RU2356908C2 (ru) Новые противоопухолевые соединения
KR101149095B1 (ko) 4-메틸헥사노 카할라리드 ｆ 화합물
HK1082261B (en) 4-methylhexanoic kahalalide f compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100224

Termination date: 20161020

CF01 Termination of patent right due to non-payment of annual fee